Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibrosis Reduction
- Molecular classification
- Therapeutic strategy, Multi-target approach
01
Overview
Fibrosis reduction is a therapeutic goal aimed at mitigating the excessive accumulation of extracellular matrix (ECM) components, primarily collagen, that leads to tissue scarring and organ dysfunction. It involves targeting key molecular pathways and cellular processes that drive fibrogenesis, including TGF-β signaling, chemokine-mediated inflammation, integrin activation, metabolic dysregulation, and myofibroblast survival. Effective strategies often involve combination approaches that address both upstream drivers of fibrosis and downstream effectors of ECM production.
- Other names
- Antifibrotic therapyECM reductionInhibition of fibrogenesisReversal of tissue scarring
02
Mechanism of action
Inhibition of fibrogenic signaling pathways, reduction of ECM production, modulation of immune cell activity, and induction of myofibroblast apoptosis or inactivation.
03
Biological functions
Inhibition of extracellular matrix depositionReduction of myofibroblast activityModulation of immune response in fibrotic tissuesPrevention of tissue scarringReversal of tissue remodeling
04
Disease associations
Idiopathic pulmonary fibrosis (IPF)Liver cirrhosisChronic kidney diseaseSystemic sclerosisCardiac fibrosisOther fibrotic diseases
05
Safety considerations
Off-target effects due to broad signaling pathway modulationIncreased risk of infection due to immune suppressionPotential for exacerbation of other disease processesDevelopment of drug resistanceLack of long-term efficacy dataOrgan-specific toxicity
06
Interacting drugs
TGF-β inhibitors
8 more in the full profile.
07
Biomarkers
Serum collagen markers (e.g., Pro-collagen III N-terminal peptide)Matrix metalloproteinases (MMPs)Tissue inhibitors of metalloproteinases (TIMPs)Hyaluronic acidTGF-β levelsInflammatory cytokines (e.g., IL-6, TNF-α)Fibroblast markers (e.g., α-SMA)
Beyond the preview
Go deeper on Fibrosis Reduction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibrosis Reduction.